Malaysia Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Malaysia Breast Cancer Therapeutics Market Analysis

$ 3999

The Malaysia breast cancer therapeutics market is expected to grow from $29 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The rising incomes and continuously improving healthcare infrastructure in Malaysia are major market drivers in the breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Royce Pharma Manufacturing, Johnson & Johnson Private Limited, and Cipla are some of the leading companies in the Malaysia breast cancer therapeutics market.

ID: IN10MYPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Parul Choudhary

Buy Now

Malaysia Breast Cancer Therapeutics Market Executive Analysis

The Malaysia breast cancer therapeutics market size is at around $29 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The Health Ministry will receive one of the greatest allocation increases in budget 2023, amounting to $8.38 Bn compared to $7.52 Bn this year, as the government of Malaysia continues to improve the capacity of public health services. To increase healthcare capacity, $1.14 Bn had been set aside. This included buying drugs, lab equipment, and vaccines, among other things. This allotment has been increased by 12% from 2022. The budget for building new hospitals, clinics, and healthcare facilities is $0.42 Bn. The PekaB40 health program received $18.57 Mn, which included funding for diabetes screening.

For Malaysian women, breast cancer continues to be the primary cause of cancer mortality. 3,500 people are thought to pass away from breast cancer each year, or more than 9 people every day. One significant factor is that Malaysian breast cancer patients are more likely to present with late-stage disease, which has a lesser probability of being cured, and another one is the country's restricted access to life-saving medicines. Stage IV breast cancer that has progressed to other organs is referred to as advanced breast cancer (ABC). Lungs, the liver, bones, and the brain are frequent locations where breast cancer spreads. Even though the cancer is incurable at this point, improvements in treatment choices like chemotherapy, radiotherapy, immunotherapy, and targeted medicines have greatly enhanced patient outcomes in Malaysia. Less adverse effects are associated with improvements in treatment responses and survival, which helps patients retain a high standard of living.

malaysia breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Malaysia breast cancer therapeutics market is anticipated to expand throughout the projected period as a result of rising disposable incomes and a constantly developing healthcare infrastructure. During the projection period, the immunotherapy market is anticipated to expand in demand. Comparing immunotherapeutics to chemotherapeutics, the former has a tendency to cause fewer side effects. Chemotherapeutics' non-specificity, harmful side effects, and development of resistance are anticipated to slow their rise and increase the use of immunotherapies and other targeted therapies. This expands the breast cancer therapeutics market's window of opportunity in Malaysia.

Market Restraints

The development of the Malaysia breast cancer therapeutics market for treating breast cancer over the forecast period may be restricted by the lack of specialists who are unfamiliar with the best treatment options available for the illness. The market expansion is also hampered by numerous medications' patent expiry dates.

Competitive Landscape

Key Players

Hoe Pharmaceuticals (MYS)
Noripharma (MYS)
Prime Pharmaceutical (MYS)
Royce Pharma Manufacturing (MYS)
Johnson & Johnson
Cipla
Abbott
AbbVie

Healthcare Policies and Regulatory Landscape

Malaysia combines government-financed public service delivery with the provision of privately funded private services in addition to having a low amount of government funding for health care and a heavy reliance on household out-of-pocket spending for funding. Breast cancer treatment is covered by the government in Malaysia via the MyCare public healthcare program. This includes having access to medical procedures like surgery, radiotherapy, and chemotherapy. Through the Bantuan Rawatan Kanser (Cancer Treatment Assistance) program, the government additionally offers financial aid to low-income people who are diagnosed with breast cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.